A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
NCT00498615 is a phase 3 interventional trial sponsored by Johns Hopkins University. As of 18 Nov 2026, it is completed. It studies Fasudil in Raynaud and Scleroderma. The registry lists an enrollment of 17 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2007 and a primary completion date of 31 Mar 2012.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00498615 |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Johns Hopkins University |
| Enrollment | 17 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Raynaud and Scleroderma |
| Drugs | Fasudil |
| Start | 30 Apr 2007 |
| Primary completion | 31 Mar 2012 |
| Study completion | 31 Mar 2012 |
| Last update posted | 4 Nov 2014 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Fredrick M Wigley, M.D.
Johns Hopkins University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University
Baltimore
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00498615
Each answer restates registry values shown on this page.
What is NCT00498615?
NCT00498615 is a phase 3 interventional trial sponsored by Johns Hopkins University. It studies Fasudil in Raynaud and Scleroderma.
Who leads NCT00498615?
The registry names Fredrick M Wigley, M.D. (principal investigator, Johns Hopkins University) as the overall official.
Where does NCT00498615 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00498615 study?
The registered drug and biological interventions are Fasudil.
When did NCT00498615 end?
The registry lists a primary completion date of 31 Mar 2012 and a study completion date of 31 Mar 2012. The sponsor last updated the record on 4 Nov 2014.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.